STAT1 and colorectal cancer: For example, Liang et al. demonstrated the use of a proteasome inhibitor, bortezomib, to restore STAT1 expression in colorectal cancer, leading to an increase in major histocompatibility complex (MHC) I expression for subsequent immunological activation [33].